| Stimuli | Increased secretomes | Reference |
| Hypoxia | Tropomyosin, VEGF, SDF-1, FGF-2, HGF, IGF-1, Oct-4, Rex-1, and IDO | [88, 90–93] | IFN-γ | IDO, PGE-2, and Gal-9 | [93–96] | TNF-α | Gal-9, BMP-2, VEGF, SDF-1, FGF-2, HGF, and IGF-1 | [91, 96, 97] | TLR signal | Gal-9 | [96] | Inflammatory stimuli (IL-1β, IL-6, IL-20, and TNF-α) | CXCL-16, GRO, ENA-78, MIP-1-delta, osteoprotegerin, MCP-1, MCP-2, MCP-3, IL-6, GCP-2, and IL-2RA | [98] | LPS | VEGF, SDF-1, FGF-2, HGF, and IGF-1 | [91] | 3D culture | TSG-6, STC1, TRIL, IL-24, and CD82 | [100–102] | Nanosilicate | More than 4000 gene expression change | [103] | Aging | Increase: miR-335 | [85, 86] | Decrease: TNFR, IFNGR, CCR7, miR-146a, miR-155, and miR-132 | TGF-β | Cytoskeletal factors (e.g. T-platin, gelsolin) | [99] | Matrix synthesis factors (e.g., collagen-binding protein 2) | Membrane proteins (e.g., annexin A6, annexin A2) | Metabolic enzymes (e.g., thioredoxin reductase, transaldolase, and malate dehydrogenase) |
|
|